Clinical Trial

A Study of SKB518 in Patients With Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB518 in patients with lung cancer. Eligible subjects will receive SKB518 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-05; most recent amendment 2026-05-05.
Status change: Not Yet Recruiting → Recruiting 2025-12-01
Trial Details
NCT Number NCT07019675
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Lung Carcinoma
Enrollment 192 participants
Start Date 2025-08-29
Primary Completion 2027-02-20 (estimated)
Study Completion 2027-10-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-08